Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
07 January 2022 - 12:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and other viral diseases, today announced
that John McHutchison, AO, MD, chief executive officer and
president, will present during the HC Wainwright Virtual BIOCONNECT
Conference, January 10-13, 2022.
The presentation will be available for on-demand viewing
beginning Monday, January 10, 2022 at 7:00 a.m. EST in the Events
and Presentations section of the Company’s website at
www.assemblybio.com.
About Assembly BiosciencesAssembly Bio is
a clinical-stage biotechnology company committed to bringing finite
and curative therapies to the 270 million people living with
hepatitis B virus (HBV) worldwide. A pioneer in the development of
a new class of potent, oral core inhibitor drug candidates,
Assembly Bio’s approach aims to break the complex viral replication
cycle of HBV to free patients from a lifetime of therapy. Assembly
Bio’s strategy includes a leading portfolio of more potent,
next-generation core inhibitors, proof-of-concept combination
studies for HBV cure and research programs focused on the discovery
of additional novel antiviral mechanisms for HBV, and other viral
diseases. For more information,
visit assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to materially differ. These risks and uncertainties
include: Assembly Bio’s ability to initiate and complete
clinical studies involving its therapeutic product candidates,
including studies contemplated by Assembly Bio’s clinical
collaboration agreements, in the currently anticipated timeframes;
safety and efficacy data from clinical studies may not warrant
further development of Assembly Bio’s product candidates; clinical
and nonclinical data presented at conferences may not differentiate
Assembly Bio’s product candidates from other companies’ candidates;
results of nonclinical studies may not be representative of disease
behavior in a clinical setting and may not be predictive of the
outcomes of clinical studies; continued development and
commercialization of Assembly Bio’s HBV product candidates, if
successful, in the China territory will be dependent on, and
subject to, Assembly Bio’s collaboration agreement governing its
HBV-related activity in the China territory; Assembly Bio’s ability
to maintain financial resources necessary to continue its clinical
studies and fund business operations; any impact that the COVID-19
pandemic may have on Assembly Bio’s business and operations,
including initiation, enrollment and continuation of its clinical
studies or timing of discussions with regulatory authorities; and
other risks identified from time to time in Assembly Bio’s reports
filed with the U.S. Securities and Exchange
Commission (the SEC). You are urged to consider
statements that include the words may, will, would, could, should,
might, believes, hopes, estimates, projects, potential, expects,
plans, anticipates, intends, continues, forecast, designed, goal or
the negative of those words or other comparable words to be
uncertain and forward-looking. Assembly Bio intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. More information about Assembly Bio’s risks and
uncertainties are more fully detailed under the heading “Risk
Factors” in Assembly Bio’s filings with the SEC, including its
most recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and Current Reports on Form 8-K. Except as required by law,
Assembly Bio assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Investor and Corporate:Lauren GlaserSenior Vice President,
Investor Relations and Corporate Affairs(415)
521-3828lglaser@assemblybio.com
Media:Sam Brown Inc. Audra Friis (917)
519-9577 ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024